Repligen Seeks Preliminary Injunction Against Bristol’s RA Therapy Orencia
This article was originally published in The Pink Sheet Daily
Executive Summary
Repligen says Bristol’s abatacept infringes Repligen’s patent for method of treating rheumatoid arthritis.